drugset / Trial / NCT00311896
Efficacy & Safety of Prophylaxis With Bemiparin in Cancer Patients With a Central Venous Catheter (BECAT)
Phase 3
Terminated
402 enrolled
Clinica Universidad de Navarra, Universidad de Navarra
Laboratorio farmacéutico ROVI · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
The purpose of this study is to evaluate the efficacy and safety of the subcutaneous administration for 45 days of Bemiparin (3,500 UI/day) in cancer patients with a CVC, to prevent CVC-related deep venous thrombosis (CVC-DVT)
Timeline
- Start
- 2005-07
- Primary completion
- 2009-02
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bemiparin | Other / unclassified | 3500 iu | Subcutaneous |